Evidence map›Paper›PMID 36918825›Full record

Observational studyBMC public health2023

Psychotropic consumption before and during COVID-19 in Asturias, Spain.

María Luisa Nicieza García, Paula Fernández Martínez, Eva Fernández Bretón, Marta M Martínez Alfonso, Patricio Suárez Gil

Open access · goldFull text readObservational Study
In one paragraph

Observational study in BMC public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

María Luisa Nicieza GarcíaHealth Department, General Directorate of Health Policy and Planning, Asturias, Spain. marisa.nicieza@gmail.com.
Paula Fernández MartínezBiostatistics and Epidemiology Platform, Health Research Institute of Asturias, Asturias, Spain.
Eva Fernández BretónBiostatistics and Epidemiology Platform, Health Research Institute of Asturias, Asturias, Spain.
Marta M Martínez AlfonsoHealth Department, General Directorate of Health Policy and Planning, Asturias, Spain.
Patricio Suárez GilBiostatistics and Epidemiology Platform, Health Research Institute of Asturias, Asturias, Spain.
Gobierno del Principado de Asturias · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSpain as multiple other countries has been experiencing an increasing and sustained trend in the use of psychotropic medications since the mid 90s. Recent studies show public health measures implemented to control SARS-Cov2, such as mobility restrictions and the shutdown of nonessential activities increased mental suffering, even contributing to a higher number of anxiety, depression and insomnia disorders that could lead to an increase in the consumption of psychotropics. The aims were: 1) Evaluate the temporal trend in psychotropic consumption by pharmacological subgroup, sex, and age group 2) Estimate the effect of the COVID-19 pandemic in the use of psychotropic drugs.

methodsWe conducted a retrospective observational study, retrieving all prescriptions of anxiolytics, hypnotics and sedatives, and antidepressants dispensed in pharmacies of Asturias (Northern Spain) for Primary Care patients for the period 2018-2021. We presented the data expressed in Daily Defined Doses (DDDs) for 1000 persons/day (DHD). To estimate changes in DHDs by year and age group we conducted two multiple linear regressions (one for males and one for females) for every pharmacological subgroup studied. Changes were considered statistically significant when the regression coefficient was p < 0.05. We used the Software R 4.1.0.

resultsFor the studied period, the highest DHDs are for antidepressants, although all of the subgroups experienced an increase in consumption rates. Women consumed more psychotropic drugs than men. In 2021, 372 out of every 1000 women were taking daily 1 DDD of these drugs versus 184 out of every 1000 men. Consumption rates for all psychotropic drugs progressively increases with age. Conversely, the biggest increases in consumption were among the youngest age groups (0-14 and 15-29 years) for women, while for men there is more variability. The regression models suggest an upward trend in psychotropic consumption during all the period, especially remarkable from 2020, for both genders and all age groups.

conclusions- The consumption of psychotropic drugs has gradually increased over the last 4 years, with a significant boost starting in 2020 for both sexes, matching the start of the SARS-COV2 pandemic and the implementation of strict Public Health measures to contain it. - The increase observed on children and adolescents is a matter of concern.

Indexed as

COVID-19PandemicsAdolescentAntidepressive AgentsChildFemaleHumansHypnotics and SedativesMalePsychotropic DrugsRNA, ViralSARS-CoV-2SpainAntidepressive AgentsHypnotics and SedativesPsychotropic DrugsRNA, ViralAnti-anxiety agentsAntidepressive agentsDrug prescriptionsHypnotics and sedativesPrimary health care

Identifiers

PMID36918825
PMCPMC10014411
OpenAlexW4324306031

What OpenQuestion holds

Textfull text, public
LicenceCC BY
reference markers read1
measurements read39
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.